JP2008537546A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008537546A5 JP2008537546A5 JP2008502334A JP2008502334A JP2008537546A5 JP 2008537546 A5 JP2008537546 A5 JP 2008537546A5 JP 2008502334 A JP2008502334 A JP 2008502334A JP 2008502334 A JP2008502334 A JP 2008502334A JP 2008537546 A5 JP2008537546 A5 JP 2008537546A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- tumor
- associated antigen
- antibody
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical group 0.000 claims 108
- 108020004707 nucleic acids Proteins 0.000 claims 97
- 102000039446 nucleic acids Human genes 0.000 claims 97
- 206010028980 Neoplasm Diseases 0.000 claims 60
- 239000000427 antigen Substances 0.000 claims 54
- 102000036639 antigens Human genes 0.000 claims 54
- 108091007433 antigens Proteins 0.000 claims 54
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 238000000034 method Methods 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 102000004169 proteins and genes Human genes 0.000 claims 13
- 108090000623 proteins and genes Proteins 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 230000000295 complement effect Effects 0.000 claims 10
- 229920001184 polypeptide Polymers 0.000 claims 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims 10
- 238000001514 detection method Methods 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 230000002159 abnormal effect Effects 0.000 claims 4
- 239000000032 diagnostic agent Substances 0.000 claims 4
- 229940039227 diagnostic agent Drugs 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 3
- 231100000433 cytotoxic Toxicity 0.000 claims 3
- 230000001472 cytotoxic effect Effects 0.000 claims 3
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 3
- 210000004698 lymphocyte Anatomy 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 108020004511 Recombinant DNA Proteins 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 102000053602 DNA Human genes 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000008275 breast carcinoma Diseases 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 238000004581 coalescence Methods 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000023958 prostate neoplasm Diseases 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 230000001875 tumorinhibitory effect Effects 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005013846A DE102005013846A1 (de) | 2005-03-24 | 2005-03-24 | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
| DE102005013846.2 | 2005-03-24 | ||
| PCT/EP2006/002695 WO2006100089A2 (de) | 2005-03-24 | 2006-03-23 | Identifizierung von oberflächen-assoziierten antigenen für die tumordiagnose und -therapie |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012083549A Division JP5731436B2 (ja) | 2005-03-24 | 2012-04-02 | 腫瘍診断と治療のための表面関連抗原の同定 |
| JP2012258431A Division JP5779167B2 (ja) | 2005-03-24 | 2012-11-27 | 腫瘍診断と治療のための表面関連抗原の同定 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008537546A JP2008537546A (ja) | 2008-09-18 |
| JP2008537546A5 true JP2008537546A5 (OSRAM) | 2009-04-30 |
| JP5253999B2 JP5253999B2 (ja) | 2013-07-31 |
Family
ID=36613498
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008502334A Active JP5253999B2 (ja) | 2005-03-24 | 2006-03-23 | 腫瘍診断と治療のための表面関連抗原の同定 |
| JP2012083549A Active JP5731436B2 (ja) | 2005-03-24 | 2012-04-02 | 腫瘍診断と治療のための表面関連抗原の同定 |
| JP2012258431A Active JP5779167B2 (ja) | 2005-03-24 | 2012-11-27 | 腫瘍診断と治療のための表面関連抗原の同定 |
| JP2014005640A Active JP5922159B2 (ja) | 2005-03-24 | 2014-01-16 | 腫瘍診断と治療のための表面関連抗原の同定 |
| JP2016032631A Active JP6174177B2 (ja) | 2005-03-24 | 2016-02-24 | 腫瘍診断と治療のための表面関連抗原の同定 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012083549A Active JP5731436B2 (ja) | 2005-03-24 | 2012-04-02 | 腫瘍診断と治療のための表面関連抗原の同定 |
| JP2012258431A Active JP5779167B2 (ja) | 2005-03-24 | 2012-11-27 | 腫瘍診断と治療のための表面関連抗原の同定 |
| JP2014005640A Active JP5922159B2 (ja) | 2005-03-24 | 2014-01-16 | 腫瘍診断と治療のための表面関連抗原の同定 |
| JP2016032631A Active JP6174177B2 (ja) | 2005-03-24 | 2016-02-24 | 腫瘍診断と治療のための表面関連抗原の同定 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US9090940B2 (OSRAM) |
| EP (5) | EP2314309A3 (OSRAM) |
| JP (5) | JP5253999B2 (OSRAM) |
| DE (1) | DE102005013846A1 (OSRAM) |
| ES (1) | ES2537319T3 (OSRAM) |
| WO (1) | WO2006100089A2 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005013846A1 (de) | 2005-03-24 | 2006-10-05 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
| DE102006060824B4 (de) * | 2006-12-21 | 2011-06-01 | Johannes-Gutenberg-Universität Mainz | Nachweis von individuellen T-Zell-Reaktionsmustern gegen Tumor-assoziierte Antigene (TAA) in Tumorpatienten als Basis für die individuelle therapeutische Vakzinierung von Patienten |
| EP2060583A1 (en) * | 2007-10-23 | 2009-05-20 | Ganymed Pharmaceuticals AG | Identification of tumor-associated markers for diagnosis and therapy |
| EP2249159A1 (en) * | 2009-04-29 | 2010-11-10 | Ganymed Pharmaceuticals AG | Identification of tumor-associated markers for diagnosis and therapy |
| PT2459208T (pt) | 2009-07-29 | 2017-01-03 | Kai Pharmaceuticals Inc | Agentes terapêuticos para redução dos niveis de hormona paratiroideia |
| US8486657B2 (en) * | 2010-03-22 | 2013-07-16 | Xiaohong Cai | Anti-preproprotein and anti-preprotein antibodies as immunohistochemical markers |
| TW201302800A (zh) | 2011-06-10 | 2013-01-16 | Oncotherapy Science Inc | Ｓｅｍａ５ｂ胜肽及含其之疫苗 |
| KR20150091311A (ko) * | 2012-12-04 | 2015-08-10 | 온코세라피 사이언스 가부시키가이샤 | Sema5b 펩타이드 및 이를 포함하는 백신 |
| JP6164759B2 (ja) | 2013-11-21 | 2017-07-19 | Ｒｅｐｅｒｔｏｉｒｅ Ｇｅｎｅｓｉｓ株式会社 | Ｔ細胞受容体およびｂ細胞受容体レパトアの解析システムならびにその治療および診断への利用 |
| JP6858128B2 (ja) | 2015-02-18 | 2021-04-14 | エンリヴェックス セラピューティクス リミテッド | 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| CN113106053A (zh) | 2015-04-21 | 2021-07-13 | 恩立夫克治疗有限责任公司 | 治疗性汇集的血液凋亡细胞制剂与其用途 |
| GB201520568D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd | Peptides |
| GB201520550D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520564D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| MX2018007204A (es) | 2015-12-16 | 2018-12-11 | Gritstone Oncology Inc | Identificacion, fabricacion y uso de neoantigeno. |
| WO2017123808A1 (en) | 2016-01-15 | 2017-07-20 | The J. David Gladstone Institutes | Methods of treating disease by metabolic control of t-cell differentiation |
| EP3416661A4 (en) | 2016-02-18 | 2020-03-04 | Enlivex Therapeutics Ltd. | COMBINATION OF IMMUNOTHERAPY AND CYTOKINE CONTROL THERAPY FOR THE TREATMENT OF CANCER |
| PE20200693A1 (es) * | 2017-07-07 | 2020-06-11 | Immatics Biotechnologies Gmbh | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de pulmon, incluyendo el nsclc, el sclc y otros canceres |
| AU2018348165B2 (en) | 2017-10-10 | 2025-09-04 | Seattle Project Corp. | Neoantigen identification using hotspots |
| US11885815B2 (en) | 2017-11-22 | 2024-01-30 | Gritstone Bio, Inc. | Reducing junction epitope presentation for neoantigens |
| WO2022256620A1 (en) * | 2021-06-03 | 2022-12-08 | The Broad Institute, Inc. | Novel targets for enhancing anti-tumor immunity |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2191A (en) | 1841-07-23 | Constructing the surgical instrument denominated the | ||
| GB9019812D0 (en) | 1990-09-11 | 1990-10-24 | Scotgen Ltd | Novel antibodies for treatment and prevention of infection in animals and man |
| US5677139A (en) | 1995-04-21 | 1997-10-14 | President And Fellows Of Harvard College | In vitro differentiation of CD34+ progenitor cells into T lymphocytes |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| DE69723230T2 (de) | 1996-01-17 | 2004-05-27 | Imperial College Innovations Ltd. | Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl) |
| JP2002514073A (ja) * | 1997-02-24 | 2002-05-14 | ジェネティックス・インスチチュート・インコーポレーテッド | 分泌蛋白およびそれらをコードするポリヌクレオチド |
| JP2002512524A (ja) | 1997-06-03 | 2002-04-23 | 財団法人相模中央化学研究所 | 膜貫通ドメインを有するヒト蛋白質及びそれをコードするｄｎａ |
| JP2002539767A (ja) * | 1998-12-22 | 2002-11-26 | ジェンセット | シグナルペプチドを含む相補的ｄｎａのコードタンパク質 |
| US20030204075A9 (en) | 1999-08-09 | 2003-10-30 | The Snp Consortium | Identification and mapping of single nucleotide polymorphisms in the human genome |
| WO2002012343A2 (en) * | 2000-08-07 | 2002-02-14 | Curagen Corporation | Proteins and nucleic acids encoding g-protein coupled receptors |
| USH2191H1 (en) | 2000-10-24 | 2007-06-05 | Snp Consortium | Identification and mapping of single nucleotide polymorphisms in the human genome |
| AU2002255478A1 (en) * | 2001-01-10 | 2002-09-12 | Pe Corporation (Ny) | Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof |
| AU2002309583A1 (en) | 2001-04-18 | 2002-11-05 | Protein Desing Labs, Inc. | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
| ATE503023T1 (de) * | 2001-06-18 | 2011-04-15 | Rosetta Inpharmatics Llc | Diagnose und prognose von brustkrebspatientinnen |
| US7171311B2 (en) * | 2001-06-18 | 2007-01-30 | Rosetta Inpharmatics Llc | Methods of assigning treatment to breast cancer patients |
| US20040076955A1 (en) | 2001-07-03 | 2004-04-22 | Eos Biotechnology, Inc. | Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer |
| DE10211088A1 (de) * | 2002-03-13 | 2003-09-25 | Ugur Sahin | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| DE10254601A1 (de) * | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| WO2005021793A1 (en) | 2003-08-29 | 2005-03-10 | Pantarhei Bioscience B.V. | Prenatal diagnosis of down syndrome by detection of fetal rna markers in maternal blood |
| DE10344799A1 (de) * | 2003-09-26 | 2005-04-14 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
| DE102005013846A1 (de) | 2005-03-24 | 2006-10-05 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
-
2005
- 2005-03-24 DE DE102005013846A patent/DE102005013846A1/de not_active Ceased
-
2006
- 2006-03-23 WO PCT/EP2006/002695 patent/WO2006100089A2/de not_active Ceased
- 2006-03-23 EP EP10010914A patent/EP2314309A3/de not_active Withdrawn
- 2006-03-23 EP EP06723678.6A patent/EP1861118B1/de active Active
- 2006-03-23 ES ES06723678.6T patent/ES2537319T3/es active Active
- 2006-03-23 EP EP10010915A patent/EP2314310A3/de not_active Withdrawn
- 2006-03-23 EP EP20100010912 patent/EP2327417B1/de active Active
- 2006-03-23 US US11/886,758 patent/US9090940B2/en active Active
- 2006-03-23 JP JP2008502334A patent/JP5253999B2/ja active Active
- 2006-03-23 EP EP10010913A patent/EP2311487A3/de not_active Withdrawn
-
2012
- 2012-04-02 JP JP2012083549A patent/JP5731436B2/ja active Active
- 2012-11-27 JP JP2012258431A patent/JP5779167B2/ja active Active
-
2013
- 2013-04-17 US US13/864,411 patent/US9194004B2/en active Active
-
2014
- 2014-01-16 JP JP2014005640A patent/JP5922159B2/ja active Active
-
2015
- 2015-06-19 US US14/744,845 patent/US10036753B2/en active Active
-
2016
- 2016-02-24 JP JP2016032631A patent/JP6174177B2/ja active Active
- 2016-03-07 US US14/887,979 patent/US10302647B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008537546A5 (OSRAM) | ||
| JP2007506417A5 (OSRAM) | ||
| JP2007537197A5 (OSRAM) | ||
| JP2010047597A5 (OSRAM) | ||
| JP2006516190A5 (OSRAM) | ||
| JP5498018B2 (ja) | 胎盤成長因子（ＰｌＧＦ）媒介性の転移および／または血管新生の阻害 | |
| JP2008508861A5 (OSRAM) | ||
| US9663584B2 (en) | Antibodies to non-functional P2X7 receptor | |
| RU2008114318A (ru) | Идентификация опухолевых антигенов для диагностики и терапии | |
| JP6336696B2 (ja) | がんおよび自己免疫疾患の診断および治療に使用するためのモノクローナル抗体 | |
| JP2010063458A5 (OSRAM) | ||
| JP6832887B2 (ja) | 改変ａｘｌペプチド及び抗転移療法のａｘｌシグナル伝達阻害におけるその使用 | |
| JP7271446B2 (ja) | Ｈｌａ－ｇ転写物およびアイソフォームおよびそれらの使用 | |
| JP2005519608A5 (OSRAM) | ||
| CN105744944A (zh) | 免疫系统调节器 | |
| JP2007526759A5 (OSRAM) | ||
| CN114650842A (zh) | 抗tim-3抗体 | |
| JP2008527998A (ja) | Ｎｓｃｌｃの診断のためのｇｉｔｒ抗体 | |
| CN120137035A (zh) | 一种抗犬pd-1抗体及其用途 | |
| JP2012525121A5 (OSRAM) | ||
| EP1337850B1 (en) | Method for diagnosing a tumor in a patient determining the concentration of pibf | |
| US20220363767A1 (en) | Hla-h, hla-j, hla-l, hla-v and hla-y as therapeutic and diagnostic targets | |
| JP2008509659A5 (OSRAM) | ||
| CN114502781A (zh) | 个人化癌症免疫治疗 | |
| CN101161283B (zh) | CMTM1-v17的新应用及其拮抗剂 |